pharma news today glp-1 2025 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP1 agonists set to become

Acknowledging patients' concerns and discussing their issues should help them know that they have been heard, and it is helpful in breaking down barriers

Employee Sentiment and Retention Risks A recent Employee Benefit Research Institute (EBRI) study found that 64% of employees believe GLP1s should be included in their health plan coverage, yet nearly half of respondents were unsure if their current plan provided access

Wegovy contains the same semaglutide as Ozempic but at higher doses approved specifically for weight management

E11.42 (polyneuropathy) E11.3212 (moderate NPDR, left eye, no macular edema) E11.12 (diabetic CKD stage 3) N18.3 (CKD stage 3, required companion) Z79.4 (long-term insulin, only Z79.4 needed when on both insulin and oral agents per official guidelines) Note: Z79.84 is NOT added here because per ICD-10-CM Official Guidelines, when a patient uses both insulin and oral hypoglycemics, only Z79.4 is assigned